Related Experiment Video

Updated: Aug 21, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke

Jeffrey J Cavendish1, Steven C Cramer, Glenn D Graham

  • 1Department of Cardiology, Naval Medical Center, San Diego, CA 92134, USA. JJCavendish@nmcsd.med.navy.mil

Current Medical Research and Opinion
|November 13, 2004
PubMed

Insights

Transient ischemic attacks are key risk factors for ischemic stroke. Antiplatelet agents like clopidogrel, aspirin, and dipyridamole are crucial for preventing recurrent strokes when acute treatments are unavailable.

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Public Health

Background:

  • Cerebrovascular disease encompasses diverse etiologies, with ischemic stroke being the most prevalent.
  • Transient ischemic attack (TIA) is recognized as a significant precursor and long-term risk factor for subsequent ischemic stroke.

Observation:

  • Acute therapeutic options for ischemic stroke remain limited.
  • Current management strategies emphasize secondary prevention.

Findings:

  • Secondary prevention involves comprehensive risk-factor management, pharmacotherapy, and interventional techniques.
  • Antiplatelet agents, including clopidogrel, aspirin, and dipyridamole, form the foundation of therapy for preventing recurrent ischemic events.

Implications:

  • Effective secondary prevention is vital for reducing stroke recurrence and improving patient outcomes.
  • The role of antiplatelet therapy in managing patients at risk for ischemic stroke is well-established.
  • Further research may explore novel therapeutic targets and personalized prevention strategies for cerebrovascular disease.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.